Arriving in the field of obesity treatment, retatrutide represents a different method. Different from many available medications, retatrutide functions as a double agonist, concurrently targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) receptors. The dual stimulation fosters multiple advantageous